OBJECTIVE: To evaluate the efficacy of two commonly employed treatments for Helicobacter pylori infection and the impact of bacterial resistance to antibiotics on eradication rate. METHODS:Ninety-two consecutive H. pylori-positive patients with active peptic ulcer disease were randomly enrolled to receive a 7-day treatment with either lansoprazole 30 mg plus amoxicillin 1 g and clarithromycin 500 mg [all twice a day (b.i.d.), Group A, n = 46]; or bismuth subcitrate 125 mg four times a day (q.i.d.) plus tetracycline 500 mg q.i.d and furazolidone 200 mg b.i.d. (Group B, n = 46) H. pylori status was reassessed 30 days after completion of the therapy and bacterial resistance to the antibiotics was investigated using an in vitro assay. RESULTS: Five patients from each study group were lost to follow up. Both treatments resulted in similar H. pylori eradication rate: 66-60% (per protocol), 59-52% (intention-to-treat) in Groups A and B, respectively (non significant). However, eradication improved to 79% in the absence of H. pylori resistance to clarithromycin or amoxicillin. CONCLUSION: Primary resistance to clarithromycin or amoxicillin may underscore a potentially serious problem for the eradication of H. pylori infection. Testing for bacterial resistance may become necessary to improve therapeutic efficacy.
RCT Entities:
OBJECTIVE: To evaluate the efficacy of two commonly employed treatments for Helicobacter pylori infection and the impact of bacterial resistance to antibiotics on eradication rate. METHODS: Ninety-two consecutive H. pylori-positive patients with active peptic ulcer disease were randomly enrolled to receive a 7-day treatment with either lansoprazole 30 mg plus amoxicillin 1 g and clarithromycin 500 mg [all twice a day (b.i.d.), Group A, n = 46]; or bismuth subcitrate 125 mg four times a day (q.i.d.) plus tetracycline 500 mg q.i.d and furazolidone 200 mg b.i.d. (Group B, n = 46) H. pylori status was reassessed 30 days after completion of the therapy and bacterial resistance to the antibiotics was investigated using an in vitro assay. RESULTS: Five patients from each study group were lost to follow up. Both treatments resulted in similar H. pylori eradication rate: 66-60% (per protocol), 59-52% (intention-to-treat) in Groups A and B, respectively (non significant). However, eradication improved to 79% in the absence of H. pylori resistance to clarithromycin or amoxicillin. CONCLUSION: Primary resistance to clarithromycin or amoxicillin may underscore a potentially serious problem for the eradication of H. pyloriinfection. Testing for bacterial resistance may become necessary to improve therapeutic efficacy.
Authors: K Van den Bulck; A Decostere; I Gruntar; M Baele; B Krt; R Ducatelle; F Haesebrouck Journal: Antimicrob Agents Chemother Date: 2005-07 Impact factor: 5.191
Authors: Atieh Makhlough; Hafez Fakheri; Ahmad Ramezani Farkhani; Omid Seddighi; Seyed Vahid Hossieni; Mohammad Khademloo; Zohreh Bari Journal: Adv Biomed Res Date: 2014-12-06
Authors: João Paulo L Damasceno; Ricardo P Rodrigues; Rita de Cássia R Gonçalves; Rodrigo R Kitagawa Journal: Molecules Date: 2017-05-12 Impact factor: 4.411
Authors: Fernando M Silva; Jaime N Eisig; Ana Cristina S Teixeira; Ricardo C Barbuti; Tomás Navarro-Rodriguez; Rejane Mattar Journal: BMC Gastroenterol Date: 2008-05-29 Impact factor: 3.067